Travere Therapeutics/$TVTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Travere Therapeutics
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
- Ticker
- $TVTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 497
- Headquarters
- San Diego, United States
- Website
- travere.com
TVTX Metrics
BasicAdvanced
$5.9bn
-
-$0.48
1.04
-
Price and volume
Market cap
$5.9bn
Beta
1.04
52-week high
$66.24
52-week low
$17.05
Average daily volume
1.6m
Financial strength
Current ratio
4.046
Quick ratio
3.763
Long term debt to equity
2,490.588
Total debt to equity
2,515.721
Interest coverage (TTM)
-4.27%
Profitability
EBITDA (TTM)
22.913
Gross margin (TTM)
59.21%
Net profit margin (TTM)
-7.35%
Operating margin (TTM)
-6.84%
Effective tax rate (TTM)
-0.90%
Revenue per employee (TTM)
$1,190,000
Management effectiveness
Return on assets (TTM)
-3.73%
Return on equity (TTM)
-236.35%
Valuation
Price to revenue (TTM)
9.589
Price to book
238.72
Price to tangible book (TTM)
-54.71
Price to free cash flow (TTM)
373.949
Free cash flow yield (TTM)
0.27%
Free cash flow per share (TTM)
0.166
Growth
Revenue change (TTM)
77.12%
Earnings per share change (TTM)
-76.17%
3-year revenue growth (CAGR)
69.94%
10-year revenue growth (CAGR)
17.22%
3-year earnings per share growth (CAGR)
-52.74%
10-year earnings per share growth (CAGR)
-15.14%
What the Analysts think about TVTX
Analyst ratings (Buy, Hold, Sell) for Travere Therapeutics stock.
TVTX Financial Performance
Revenues and expenses
TVTX Earnings Performance
Company profitability
TVTX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.